Overview

In July 2026, Health Canada issued an important notice to industry regarding information submitted with Class III and IV medical device licence applications.

The message is simple, but important: more information does not always make a stronger submission.

Health Canada stated that it has observed a significant increase in the volume of information submitted with Class III and IV medical device licence applications. The agency also warned that including large amounts of unnecessary information can delay the review process. See the Health Canada Notice to Industry: Expectations for information submitted in Class III and IV medical device licence applications.

For medical device manufacturers, this notice should be taken seriously. It reflects a broader regulatory expectation that submissions should be organized, relevant, evidence-based, and reviewer-friendly.

A medical device licence application is not supposed to be a complete dump of the design history file, technical file, risk management file, test reports, clinical literature, and every supporting document generated during development. The purpose of the application is to provide the information needed to support the safety and effectiveness of the device, in a format that allows Health Canada to conduct an efficient and meaningful review.

Submission Quality Rule: Do not submit everything you have. Submit what the reviewer needs to reach a decision.

The core issue: document volume versus submission quality

Many manufacturers assume that adding more documents makes an application stronger. In practice, excessive documentation can have the opposite effect.

If a submission contains duplicative reports, irrelevant appendices, unclear summaries, inconsistent claims, or unexplained supporting data, the reviewer must spend more time determining what matters and what does not. That can create confusion, trigger clarification requests, or delay the licensing process.

The issue is not whether the manufacturer has enough evidence. The issue is whether the evidence is presented in a way that directly supports the regulatory question.

For Class III and IV devices, Health Canada expects the application to include the information required by the Medical Devices Regulations. The application should support the intended use, indications for use, device description, design and manufacturing information, risk management, safety and effectiveness evidence, clinical evidence where applicable, labelling, and other relevant regulatory requirements.

However, the submission should not include unnecessary or duplicative material simply because it exists.

1. Expectations for application content

Health Canada’s notice states that applicants should submit only the information needed to support the application.

This is an important point. A strong application is not measured by page count. It is measured by how clearly the submission answers the reviewer’s questions.

The reviewer should be able to understand:

  • What the device is
  • How the device works
  • What the intended use and indications are
  • What claims are being made
  • What evidence supports those claims
  • What risks have been identified
  • How those risks have been mitigated
  • What testing was performed
  • Why the submitted evidence is sufficient
  • How the device meets the applicable safety and effectiveness requirements

If the relevance of submitted information is unclear, Health Canada may ask for clarification. This means the manufacturer should not assume that the reviewer will search through large attachments and infer the regulatory rationale.

The application should guide the reviewer.

Panabistics perspective

Medical device submissions should be prepared with a reviewer’s workflow in mind.

Every major section should answer three basic questions:

  1. Why is this information included?
  2. What regulatory requirement or safety and effectiveness question does it support?
  3. Where is the supporting evidence located?

If a document or appendix does not help answer those questions, it should be reconsidered.

2. Avoiding unnecessary or duplicative information

Health Canada specifically warned that unnecessary or duplicative information can increase review times and delay the licensing process.

This is a common problem in medical device applications.

Examples include:

  • Repeating the same information in multiple sections without adding value
  • Including full reports when a concise summary and targeted evidence may be sufficient
  • Attaching outdated reports that do not match the final device configuration
  • Submitting supplier documents that are not clearly connected to the subject device
  • Including general literature that does not support the specific device, indication, or claim
  • Providing multiple versions of the same test report or protocol
  • Including internal development records that are not needed for the application
  • Adding excessive background material that distracts from the actual evidence

Duplication can also create risk. When the same information appears in multiple places, inconsistencies are more likely. A device description in one section may not match the labelling. A clinical claim may appear in a summary but not in the evidence table. A software version may differ between the cybersecurity documentation, verification report, and labelling.

These inconsistencies may appear minor, but they can raise reviewer questions.

Panabistics perspective

Before submitting, manufacturers should perform a submission consistency check.

This should include alignment of:

  • Device name and model numbers
  • Intended use and indications for use
  • Device description
  • Accessories and configurations
  • Software version
  • Hardware version
  • Sterility status
  • Shelf life
  • Patient-contacting materials
  • Clinical claims
  • Performance claims
  • Risk controls
  • Test article identification
  • Labelling and instructions for use

A focused submission is not a thin submission. It is a controlled submission.

3. Use of summaries and supporting evidence

Health Canada’s notice emphasizes the importance of clear and concise summaries that accurately reflect the supporting data.

This is one of the most important parts of the notice.

For Class III and IV applications, summaries are not just administrative content. They are the bridge between the raw evidence and the regulatory conclusion. A good summary helps the reviewer understand what was tested, why it matters, what the results show, and how the evidence supports safety and effectiveness.

A weak summary can create problems even when the underlying evidence is acceptable.

For example, a test report may support a performance claim, but if the summary does not clearly identify the device tested, acceptance criteria, sample size, test method, results, deviations, and conclusion, the reviewer may need to ask follow-up questions.

A summary should not exaggerate the evidence. It should not selectively describe only favorable results. It should not introduce claims that are not supported by the report. It should not replace the supporting evidence.

The summary should accurately reflect the data.

What a good evidence summary should include

For most testing or evidence sections, a strong summary should include:

  • Purpose of the test or evidence
  • Device or configuration tested
  • Applicable standard, guidance, or method
  • Acceptance criteria
  • Sample size or data source
  • Summary of results
  • Deviations or limitations, if any
  • Conclusion
  • Location of the supporting report or evidence

For clinical evidence, the summary should also explain the relevance of the data to the subject device, intended use, patient population, clinical claims, and risk profile.

For literature-based evidence, the summary should explain why the literature is applicable and how it supports the device under review.

For comparator-based arguments, the summary should clearly explain similarities, differences, and why any differences do not negatively affect safety or effectiveness.

Panabistics perspective

A submission should not force the reviewer to reconstruct the manufacturer’s argument.

The manufacturer should clearly show how each piece of evidence supports the application.

A useful approach is to create a traceability structure that connects:

  • Regulatory requirement
  • Submission section
  • Claim or device feature
  • Risk or safety and effectiveness question
  • Supporting evidence
  • Summary conclusion
  • Attachment or report location

This makes the application easier to review and reduces the chance that important evidence is overlooked. Teams preparing Canadian Class III or IV packages may benefit from a structured Clinical Evidence Review or broader Regulatory Readiness Stress Tests.

4. Use of artificial intelligence tools

Health Canada’s notice specifically addresses the use of artificial intelligence tools.

The agency states that if applicants use artificial intelligence tools to generate summaries or explanatory material, they remain responsible for ensuring that the content is accurate and reflects the supporting data.

This is a very important statement.

Artificial intelligence tools can help regulatory teams draft summaries, organize information, identify inconsistencies, and improve readability. However, AI-generated content can also introduce errors, unsupported conclusions, fabricated details, or subtle misinterpretations of technical data.

In a regulatory submission, those errors can be serious.

An AI-generated summary that sounds polished but does not accurately reflect the test report can create regulatory risk. The same is true for AI-generated clinical summaries, risk management summaries, software summaries, cybersecurity summaries, or benefit-risk explanations.

The issue is not whether AI can be used. The issue is whether the manufacturer has adequate control over the output.

Common risks when using AI tools in regulatory submissions

Manufacturers should be aware of several risks:

  • AI may summarize a document inaccurately
  • AI may omit important limitations or deviations
  • AI may overstate the strength of evidence
  • AI may introduce terminology that is not used in the source document
  • AI may create unsupported regulatory conclusions
  • AI may confuse similar device models or software versions
  • AI may mix information from different reports
  • AI may make language sound more certain than the data supports
  • AI may generate content that is inconsistent with labelling, risk management, or clinical evidence

These risks are especially important for Class III and IV devices, where the safety and effectiveness evidence is subject to more detailed review.

Recommended controls for AI-generated regulatory content

If artificial intelligence tools are used to support submission preparation, manufacturers should implement controls such as:

  • Human subject matter expert review of all AI-generated content
  • Source-to-summary verification
  • Traceability between each claim and supporting evidence
  • Version control for source documents
  • Confirmation that device names, models, and software versions are correct
  • Review of all acceptance criteria and results against the original reports
  • Identification of limitations, deviations, or unresolved issues
  • Consistency checks against labelling, intended use, risk management, and clinical claims
  • Removal of unsupported conclusions
  • Documentation of internal review and approval

AI can be useful as a drafting and organization tool, but it should not be treated as the regulatory decision-maker.

Panabistics perspective

AI-generated regulatory content should be treated like a draft prepared by a junior reviewer: useful, but not authoritative until verified.

The manufacturer remains responsible for the submission.

For high-risk medical device applications, the safest approach is to use AI to improve efficiency while maintaining human control over regulatory judgment, evidence interpretation, and final conclusions.

5. Why this matters for Class III and IV applications

Class III and IV medical device licence applications require strong evidence because these devices present higher risk.

Health Canada’s review is focused on whether the device meets the applicable safety and effectiveness requirements. If the application is unclear, overly broad, inconsistent, or filled with unnecessary information, the reviewer may need to request clarification or additional information.

That can delay the application.

For manufacturers, delays can affect launch timelines, distributor commitments, market access, revenue planning, and investor expectations.

A high-quality application should reduce friction in the review process. It should help Health Canada understand the device, evaluate the evidence, and reach a decision efficiently.

6. What manufacturers should do before submission

Before submitting a Class III or IV medical device licence application, manufacturers should perform a submission quality review.

This review should ask:

  • Is every section directly relevant to the application?
  • Are all summaries clear, concise, and accurate?
  • Do the summaries reflect the supporting evidence?
  • Are all claims supported by data?
  • Are there any duplicated or outdated attachments?
  • Are the device descriptions consistent across the application?
  • Are model numbers, accessories, and configurations aligned?
  • Are test reports clearly connected to the subject device?
  • Are deviations or limitations explained?
  • Is the clinical evidence proportionate to the device and claims?
  • Are AI-generated summaries verified against the original source documents?
  • Can the reviewer easily find the evidence supporting each major conclusion?

This review should happen before submission, not after a clarification request.

7. Practical checklist for submission quality

Manufacturers preparing Class III or IV applications should consider the following checklist:

Application content

  • Include only information needed to support the application
  • Remove irrelevant background information
  • Avoid duplicative attachments
  • Confirm that all documents reflect the final device configuration
  • Ensure each attachment has a clear purpose

Summaries

  • Use clear and concise summaries
  • Identify the source evidence
  • Summarize the method, acceptance criteria, results, and conclusion
  • Avoid unsupported claims
  • Include limitations or deviations where relevant

Evidence traceability

  • Link each major claim to supporting evidence
  • Link each risk control to verification or validation evidence
  • Link clinical claims to clinical evidence
  • Link labelling claims to supporting data
  • Confirm consistency between the application, reports, and labelling

Artificial intelligence tools

  • Verify all AI-generated content against source documents
  • Do not rely on AI-generated conclusions without expert review
  • Check for hallucinated or unsupported statements
  • Confirm device names, models, software versions, and test article details
  • Maintain human accountability for final submission content

Final review

  • Perform a reviewer-readiness check
  • Confirm that the application tells a coherent regulatory story
  • Remove content that creates confusion without adding evidence
  • Ensure the submission is complete, focused, and defensible

Conclusion

Health Canada’s July 2026 notice is a timely reminder that submission quality matters.

For Class III and IV medical device licence applications, manufacturers should not assume that more information means a better application. Excessive, duplicative, unclear, or poorly summarized information can slow the review process and create unnecessary questions.

A strong submission is focused, accurate, traceable, and reviewer-friendly.

Artificial intelligence tools may help prepare summaries and explanatory content, but manufacturers remain responsible for ensuring that those summaries accurately reflect the supporting evidence.

The regulatory team’s job is not to submit every available document. The regulatory team’s job is to present the right evidence, in the right structure, with the right explanation.

How Panabistics can help

Panabistics supports medical device companies with Health Canada medical device licence applications, Class III and IV submission readiness, evidence gap assessments, clinical evidence strategy, regulatory summaries, technical documentation review, and QMS alignment.

We help manufacturers identify gaps before regulators do.

If your team is preparing a Class III or IV medical device licence application, Panabistics can review your submission package for clarity, consistency, evidence traceability, and reviewer readiness. Explore our Regulatory Readiness Stress Tests, Clinical Evidence Review, Medical Device QMS Readiness Stress Test, MDEL services, and contact us to discuss scope.

Panabistics Corp.
Navigating the Future of MedTech Compliance

References

  • Health Canada Notice to Industry, Expectations for information submitted in Class III and IV medical device licence applications: canada.ca